Kisqali Plus Femara Seems Best Option for Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer

Breastcancer.org Podcast

Content provided by Caroline Durham. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Caroline Durham or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

2+ y ago 19:47

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on April 01, 2022 06:22 (2y ago). Last successful fetch was on February 28, 2022 07:18 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Dr. Gabriel Hortobagyi is professor of breast medical oncology at the University of Texas MD Anderson Cancer Center. He is a past president of the American Society of Clinical Oncology and is one of the world’s leading authorities on breast cancer treatment. He has published more than 1,000 papers in peer-reviewed journals. At the European Society for Medical Oncology Congress 2021, Dr. Hortobagyi presented overall survival results from the MONALEESA-2 trial, which compared the combination of Kisqali and Femara to Femara alone to treat advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women. Earlier results from the study found that adding Kisqali to Femara improved progression-free survival — the amount of time the women lived without the cancer growing. These new results found that the combination of Kisqali and Femara also improved overall survival — the length of time women lived whether the cancer grew or not. Listen to the episode to hear Dr. Hortobagyi explain: the goals of the MONALEESA-2 study why the overall survival difference of more than 1 year is so important whether the improvement in overall survival is likely to be the same no matter which aromatase inhibitor is used what the results mean for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive HER2-negative breast cancer Running time: 19:47

215 episodes

#Science #Medicine #Breast Cancer #Caroline Durham #Health and Well-Being #Podcasting Education